Latest Financial Results
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2024
Report Links
Email Alerts
Receive updates straight into your inbox
Company Overview
XORTX Therapeutics Inc. is a pharmaceutical company with four programs underway: One of these programs is at the pre-NDA filing stage – XRx-026 for the treatment of gout; two are clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection. XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and health of patients. Additional information on XORTX is available at www.xortx.com
IR Contacts
Company
XORTX Therapeutics Inc.
3710 – 33rd Street NW
Calgary, Alberta T2L 2M1
Canada
T: 403-455-7727
info@xortx.com
Investor Relations
Allen Davidoff
CEO
T: 403-455-7727
adavidoff@xortx.com
Nick Rigopulos
Director of Communications
T: 617-901-0785
nick@alpineequityadv.com
Transfer Agent
TSX Trust Company
Investor Services
100 Adelaide Street West
Suite 301
Toronto, ON M5H 4H1
Canada
T: 416-342-1091
tmxeinvestorservices@tmx.com